Ardelyx (ARDX) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ardelyx (ARDX) has outperformed MannKind (MNKD) over the past year, losing 35.4% versus a loss of 37.1%. Over five years, ARDX leads with a +202.8% price change compared with -32.8% for MNKD. MannKind is the larger company by market cap ($1.10 billion vs $844.3 million), about 1.3 times the size.
On valuation, Ardelyx trades at a lower forward P/E (11.3x vs 26.8x for MannKind).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | MNKD |
|---|---|---|
| Share price | $3.27 | $3.42 |
| Market cap | $844.27M | $1.10B |
| 1-day change | +0.31% | -0.87% |
| YTD return | -43.91% | -39.68% |
| 1-year return | -35.38% | -37.13% |
| 5-year return | +202.78% | -32.81% |
| Forward P/E | 11.26 | 26.82 |
| EPS (TTM) | $-0.23 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $6.51 |
| 52-week low | $3.18 | $2.23 |
| Distance from 52-week high | -61.07% | -47.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +294.50% | +129.24% |
| Average volume | 4.17M | 4.50M |
| Shares outstanding | 258.19M | 321.54M |
| Employees | 489 | 591 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Healthcare · Biotechnology · 489 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Healthcare · Biotechnology · 591 employees
ARDX vs MNKD FAQ
Which is bigger, Ardelyx or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.10B compared with $844.27M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or MNKD?
ARDX returned -35.38% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and MannKind in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.